免疫治疗在腹膜间皮瘤中的研究进展  

Research progress on immunotherapy for peritoneal mesothelioma

作　　者：张嘉欣 卢丽婷 巴一(综述) 王晰程(审校) Jiaxin Zhang;Liting Lu;Yi Ba;Xicheng Wang(Cancer Medical Center,Chinese Academy of Medical Sciences,Beijing 100032,China)

机构地区：[1]中国医学科学院北京协和医院肿瘤医学中心,北京市100032

出　　处：《中国肿瘤临床》2025年第1期40-46,共7页Chinese Journal of Clinical Oncology

摘　　要：腹膜间皮瘤(peritoneal mesothelioma,PeM)起源于腹膜间皮细胞,常侵入腹膜的脏层及壁层,是一种罕见且具有高度侵袭性的恶性肿瘤,约占所有间皮瘤的15%。该病发病隐匿,预后不良,具体机制未完全阐明。石棉接触被认为是间皮瘤的主要风险因素。目前,除肿瘤细胞减灭术(cytoreductive surgery,CRS)/腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)和铂类/培美曲塞为常规治疗以外,仍缺乏有效的替代治疗方案。免疫治疗通过调动患者的免疫系统,在晚期间皮瘤患者中初见疗效。然而,更多基于真实世界的临床试验和免疫治疗靶点的研究仍亟待探索。本文就PeM相关的免疫治疗临床研究进展及在PeM治疗中的潜在靶点进行综述。Peritoneal mesothelioma(PeM),which originates in cells in the visceral and mural layers of the peritoneum,is a rare and highly aggressive malignant tumor that accounts for approximately 15%of all mesotheliomas.The disease is characterized by insidious onset and poor prognosis,and its mechanisms of tumorigenesis and progression have not been fully elucidated.Asbestos exposure is a major risk factor for mesothelioma.Effective treatment options alternative to cytoreductive surgery(CRS),hyperthermic intraperitoneal chemotherapy(HIPEC),and platinum/pemetrexed(conventional treatments)are currently lacking.Immunotherapy,which mobilizes the immune system,has shown initial efficacy in patients with advanced mesotheliomas.However,additional real-world clinical trials and studies on immunotherapeutic targets remain needed.This article reviews progress in PeM-related immunotherapy clinical studies and potential targets in PeM treatment.

关 键 词：免疫治疗 腹膜间皮瘤 免疫检查点抑制剂 联合治疗 

分 类 号：R735.5[医药卫生—肿瘤]